Industries > Pharma > Antihypertensives Market Report to 2031
Antihypertensives Market Report to 2031
By Type (Diuretics, Beta-Blockers, ACE Inhibitors, Angiotensin II Receptor Blockers, Calcium Channel Blockers, Others), By End User (Retail Pharmacy, Hospitals, Others). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Global Antihypertensives Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Global Antihypertensives Market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Global Antihypertensives Market report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antihypertensives Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Antihypertensives Market by Type
• Diuretics
• Beta-blockers
• ACE inhibitors
• Angiotesin II receptor blockers
• Calcium channel blockers
• Others
Antihypertensives Market by End User
• Retail pharmacy
• Hospitals
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East and Africa
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Antihypertensives Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Antihypertensives Market with forecasts for by type, by end user type each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Global Antihypertensives Market report helps you
In summary, our 280+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Global Antihypertensives Market, with forecasts by type, and by end user each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the global antihypertensives market in North America, Europe, Asia-Pacific, and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa, among other, prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for global antihypertensives market of the major companies involved in the global antihypertensives market. Some of the company’s profiled in this report include-
• Pfizer, Inc.
• Novartis AG
• Merck & Co., Inc
• Boehringer Ingelheim GmbH
• Daiichi Sankyo Co. Ltd
• Johnson & Johnson
• AstraZeneca PLC
• AbbVie
• Cipla Limited
• Sun Pharmaceutical Industries Ltd.
• Sanofi
• Mankind Pharma
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With Information found nowhere else
our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the global Antihypertensives Market and leading companies. You will find data, trends, and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Antihypertensives Market Report to 2031: By Type (Diuretics, Beta-Blockers, ACE Inhibitors, Angiotensin II Receptor Blockers, Calcium Channel Blockers, Others), By End User (Retail Pharmacy, Hospitals, Others). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Global Antihypertensives Market
2.1. Global Antihypertensives Market Definition
2.2. By Type Submarkets Definitions
2.3. End User Submarkets Definitions
3. Global Antihypertensives Market Overview
3.1. Global Antihypertensives Market Size and Forecast by Region
3.2. Global Antihypertensives Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Change in Lifestyle, Increasing Obese Population.
3.3.1.2. Surge in Geriatric Population.
3.3.1.3. Increasing Prevalence of High Blood Pressure or Hypertension Globally.
3.3.2. Market Restraints/Challenges
3.3.2.1. Increasing Cost of Drugs, Becomes Barrier for an Effective Treatment.
3.3.3. Opportunities
3.3.3.1. High Growth of Hypertensives in Developing Economies
3.3.3.2. Increasing Demand for Hypertensives to Control Serious Health Conditions.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antihypertensives Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Diuretics
4.3. Beta-blockers
4.4. ACE inhibitors
4.5. Angiotensin II receptor blockers
4.6. Calcium channel blockers
4.7. Others
5. Global Antihypertensives Market Analysis and Forecast, 2021-2031 End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Retail Pharmacy
5.1.2. Hospitals
5.1.3. Others
6. North America Antihypertensives Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Antihypertensives Market Size and Forecast By Type
6.3. North America Antihypertensives Market Size and Forecast End User
6.4. U.S. Antihypertensives Market
6.5. Canada Antihypertensives Market
7. Europe Antihypertensives Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Antihypertensives Market Size and Forecast By Type
7.3. Europe Antihypertensives Market Size and Forecast End User
7.4. UK Antihypertensives Market
7.5. Germany Antihypertensives Market
7.6. France Antihypertensives Market
7.7. Rest of Europe Antihypertensives Market
8. Asia Pacific Antihypertensives Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Antihypertensives Market Size and Forecast By Type
8.3. Asia Pacific Antihypertensives Market Size and Forecast End User
8.4. China Antihypertensives Market
8.5. India Antihypertensives Market
8.6. Japan Antihypertensives Market
8.7. Rest of Asia Pacific Antihypertensives Market
9. Latin America Antihypertensives Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Antihypertensives Market Size and Forecast By Type
9.3. Latin America Antihypertensives Market Size and Forecast End User
9.3.1. Brazil Antihypertensives Market
9.3.2. Mexico Antihypertensives Market
9.3.3. Rest of Latin America Antihypertensives Market
10. MEA Antihypertensives Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Antihypertensives Market Size and Forecast By Type
10.2.1. Penicillin Submarket Expected to Grow at Significant Rate
10.3. MEA Antihypertensives Market Size and Forecast End User
10.4. South Africa Antihypertensives Market
10.5. Rest of MEA Antihypertensives Market
11. Companies in the Global Antihypertensives Market
11.1. Pfizer, Inc.
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.3. Financial Performance (2015-2020)
11.1.3.1. Net Revenue
11.1.4. Product Offerings
11.1.5. Recent Initiatives (2017-2020)
11.2. Novartis AG
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2020)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2020)
11.3. Merck & Co., Inc
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2020)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2020)
11.4. Boehringer Ingelheim GmbH
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2020)
11.4.3.1. Net Revenue
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2020)
11.5. Daiichi Sankyo Co. Ltd
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2020)
11.5.3.1. Net Revenue
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2020)
11.6. Johnson & Johnson
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2020)
11.6.3.1. Net Revenue
11.6.3.2. Geographical Revenue, 2020
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2020)
11.7. AstraZeneca PLC
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2020)
11.7.3.1. Net Revenue
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2020)
11.8. AbbVie
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2020)
11.8.3.1. Net Revenue
11.8.3.2. Gross Profit
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2020)
11.9. Cipla
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2020)
11.9.3.1. Net Revenue
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2020)
11.10. Sun Pharmaceutical Industries Ltd.
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2020)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2020)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 2. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antihypertensives Market Drivers & Restraints 2021
Table 7. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Diuretics Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 13. Diuretics Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Diuretics Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Diuretics Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Diuretics Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Beta-blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 18. Beta-blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Beta-blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Beta-blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Beta-blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 22. ACE inhibitors Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 23. ACE inhibitors Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 24. ACE inhibitors Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 25. ACE inhibitors Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 26. ACE inhibitors Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Angiotensin II receptor blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 28. Angiotensin II receptor blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Angiotensin II receptor blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Angiotensin II receptor blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Angiotensin II receptor blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Calcium channel blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Calcium channel blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Calcium channel blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Calcium channel blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Calcium channel blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 38. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 43. Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Retail Pharmacy Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 48. Retail Pharmacy Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Retail Pharmacy Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Retail Pharmacy Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Retail Pharmacy Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Hospitals Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 53. Hospitals Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Hospitals Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Hospitals Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Hospitals Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table58. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Regional Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 63. Regional Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Regional Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Regional Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Regional Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 67. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 68. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 69. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 70. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 71. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 72. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 73. North America Antihypertensives Market Forecast End User 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 74. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 75. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table76. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 77. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 81. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 91. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 120. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 121. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 126. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Asia Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Asia Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Asia Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Asia Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Asia Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Asia Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. Asia Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Asia Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Asia Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Asia Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 137. Asia Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Asia Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Asia Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Asia Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Asia Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. RoAPAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. RoAPAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. RoAPAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. RoAPAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. RoAPAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165 Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167 Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168 Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170 Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179 Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182 Leading 10 Antihypertensives Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 183. Pfizer Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 184. Pfizer Inc. Antihypertensives Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 185. Pfizer Inc. Antihypertensives Product Offering (Segment, Product Offerings)
Table 186. Novartis AG Profile 2020 (CEO, HQ, Founded, Website)
Table 187. Novartis AG Antihypertensives Product Offering (Segment, Product Offerings)
Table 188. Merck & Co., Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 189. Merck & Co., Antihypertensives Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 190. Merck & Co., Antihypertensives Product Offering (Segment, Product Offerings)
Table 191. Boehringer Ingelheim GmbH Profile 2020 (CEO, HQ, Founded, Website)
Table 192. Boehringer Ingelheim GmbH Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 193. Boehringer Ingelheim GmbH Antihypertensives Product Offering (Segment, Product Offerings)
Table 194. Daiichi Sankyo Co. Ltd Profile 2020 (CEO, HQ, Founded, Website)
Table 195. Daiichi Sankyo Co. Ltd Antihypertensives Product Offering (Segment, Product Offerings)
Table 196. Johnson & Johnson Profile 2020 (CEO, HQ, Founded, Website)
Table 197. Johnson & Johnson Antihypertensives Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 198 Johnson & Johnson Antihypertensives Product Offering (Segment, Product Offerings)
Table 199. AstraZeneca PLC Profile 2020 (CEO, HQ, Founded, Website)
Table 200. AstraZeneca PLC Antihypertensives Product Offering (Segment, Product Offerings)
Table 201. AbbVie Profile 2020 (CEO, HQ, Founded, Website)
Table 202. AbbVie Antihypertensives Product Offering (Segment, Product Offerings)
Table 203. Cipla Limited Profile 2020 (CEO, HQ, Founded, Website)
Table 204. Cipla Limited Antihypertensives Product Offering (Segment, Product Offerings)
Table 205. Sun Pharmaceutical Industries Ltd Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 206. Sun Pharmaceutical Industries. Total Company Sales 2015-2020 (US$M, AGR %)
Table 207. Sun Pharmaceutical Industries. Product Offering (Segment, Product Offerings)
Table 208. Other Companies Involved in the Antihypertensives Market (Company, Location)
LIST OF FIGURES
Figure 1. Antihypertensives Market Type Overview
Figure 2. Antihypertensives Market By Type Overview
Figure 3. Antihypertensives Market By End User Overview
Figure 4 Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 5. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 6. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 7. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 8. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 9. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 10. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 11. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 12. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 13. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 19. Antihypertensives Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 20. Antihypertensives Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 21. Antihypertensives Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 22. Antihypertensives Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 23. Antihypertensives Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 29. Regional Antihypertensives Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 30. Regional Antihypertensives Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 31. Regional Antihypertensives Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 32. Regional Antihypertensives Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 33. Regional Antihypertensives Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 34. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 35. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 36. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 37. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 38. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 39. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %)
Figure 40. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 41. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 42. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 43. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 44. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 45. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 46. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 47. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 48. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 49. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 50. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 51. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 52. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 53. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 54. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 55. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 56. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 57. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 58. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 59. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M)
Figure 60. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 61. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 62. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 63. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 64. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M) (Before COVID)
Figure 65. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 66. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 67. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 68. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 69. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 70. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 71. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 72. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 73. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 74. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 75. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 76. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 77. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 78. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 79. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 80. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 81. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 82. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 83. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 84. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 85. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 86. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 87. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 88. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 89. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 90. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 91. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 92. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 93. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 94 Asia-Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 95. Asia-Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 96. Asia-Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 97. Asia-Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 98. Asia-Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 99. Asia-Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 100. Asia-Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 101. Asia-Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 102. Asia-Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 103. Asia-Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 104. Asia-Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 105. Asia-Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 106. Asia-Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 107. Asia-Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 108. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 109. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 110. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 111 China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 112. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 113. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 114. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 115. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 116. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 117. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 118. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 119. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 120. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 121. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 122. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 123. Rest of APAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 124. Rest of APAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 125 Rest of APAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 126. Rest of APAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 127. Rest of APAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 128. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M)
Figure 129. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 130. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 131. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 132. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 133. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M)
Figure 134. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 135. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 136. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 137. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 138. Rest of Middle East Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 139. Rest of Middle East Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 140. Rest of Middle East Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 141. Rest of Middle East Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 142. Rest of Middle East Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 143. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M)
Figure 144. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 145. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 146. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 147. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 148. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M)
Figure 149. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 150. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 151. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 152. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 153. Rest of Latin America Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 154. Rest of Latin America Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 155. Rest of Latin America Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 156. Rest of Latin America Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 157. Rest of Latin America Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 158. Porter’s Five Force Analysis
Companies Mentioned
1. Pfizer Inc.
2. Novartis AG
3. Merck & Co., Inc
4. Boehringer Ingelheim GMBH
5. Daiichi Sankyo Co. Ltd
6. Johnson & Johnson
7. AstraZeneca plc
8. AbbVie
9. Cipla Limited
10. Sun Pharmaceutical Industries Ltd.
11. Sanofi
12. Mankind Pharma
13. Kenriz Care
14. Dr Reddy's Laboratories Ltd
15. Gilead Sciences, Inc.
16. Abbott Laboratories
17. Thermo Fisher Scientific
18. Takeda Pharmaceutical Company Ltd.
19. Astellas Pharma, Inc
20. Bayer HealthCare AG
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Global Antihypertensives Market
2.1. Global Antihypertensives Market Definition
2.2. By Type Submarkets Definitions
2.3. End User Submarkets Definitions
3. Global Antihypertensives Market Overview
3.1. Global Antihypertensives Market Size and Forecast by Region
3.2. Global Antihypertensives Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Change in Lifestyle, Increasing Obese Population.
3.3.1.2. Surge in Geriatric Population.
3.3.1.3. Increasing Prevalence of High Blood Pressure or Hypertension Globally.
3.3.2. Market Restraints/Challenges
3.3.2.1. Increasing Cost of Drugs, Becomes Barrier for an Effective Treatment.
3.3.3. Opportunities
3.3.3.1. High Growth of Hypertensives in Developing Economies
3.3.3.2. Increasing Demand for Hypertensives to Control Serious Health Conditions.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antihypertensives Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Diuretics
4.3. Beta-blockers
4.4. ACE inhibitors
4.5. Angiotensin II receptor blockers
4.6. Calcium channel blockers
4.7. Others
5. Global Antihypertensives Market Analysis and Forecast, 2021-2031 End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Retail Pharmacy
5.1.2. Hospitals
5.1.3. Others
6. North America Antihypertensives Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Antihypertensives Market Size and Forecast By Type
6.3. North America Antihypertensives Market Size and Forecast End User
6.4. U.S. Antihypertensives Market
6.5. Canada Antihypertensives Market
7. Europe Antihypertensives Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Antihypertensives Market Size and Forecast By Type
7.3. Europe Antihypertensives Market Size and Forecast End User
7.4. UK Antihypertensives Market
7.5. Germany Antihypertensives Market
7.6. France Antihypertensives Market
7.7. Rest of Europe Antihypertensives Market
8. Asia Pacific Antihypertensives Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Antihypertensives Market Size and Forecast By Type
8.3. Asia Pacific Antihypertensives Market Size and Forecast End User
8.4. China Antihypertensives Market
8.5. India Antihypertensives Market
8.6. Japan Antihypertensives Market
8.7. Rest of Asia Pacific Antihypertensives Market
9. Latin America Antihypertensives Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Antihypertensives Market Size and Forecast By Type
9.3. Latin America Antihypertensives Market Size and Forecast End User
9.3.1. Brazil Antihypertensives Market
9.3.2. Mexico Antihypertensives Market
9.3.3. Rest of Latin America Antihypertensives Market
10. MEA Antihypertensives Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Antihypertensives Market Size and Forecast By Type
10.2.1. Penicillin Submarket Expected to Grow at Significant Rate
10.3. MEA Antihypertensives Market Size and Forecast End User
10.4. South Africa Antihypertensives Market
10.5. Rest of MEA Antihypertensives Market
11. Companies in the Global Antihypertensives Market
11.1. Pfizer, Inc.
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.3. Financial Performance (2015-2020)
11.1.3.1. Net Revenue
11.1.4. Product Offerings
11.1.5. Recent Initiatives (2017-2020)
11.2. Novartis AG
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2020)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2020)
11.3. Merck & Co., Inc
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2020)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2020)
11.4. Boehringer Ingelheim GmbH
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2020)
11.4.3.1. Net Revenue
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2020)
11.5. Daiichi Sankyo Co. Ltd
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2020)
11.5.3.1. Net Revenue
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2020)
11.6. Johnson & Johnson
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2020)
11.6.3.1. Net Revenue
11.6.3.2. Geographical Revenue, 2020
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2020)
11.7. AstraZeneca PLC
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2020)
11.7.3.1. Net Revenue
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2020)
11.8. AbbVie
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2020)
11.8.3.1. Net Revenue
11.8.3.2. Gross Profit
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2020)
11.9. Cipla
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2020)
11.9.3.1. Net Revenue
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2020)
11.10. Sun Pharmaceutical Industries Ltd.
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2020)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2020)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 2. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antihypertensives Market Drivers & Restraints 2021
Table 7. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Diuretics Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 13. Diuretics Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Diuretics Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Diuretics Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Diuretics Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Beta-blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 18. Beta-blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Beta-blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Beta-blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Beta-blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 22. ACE inhibitors Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 23. ACE inhibitors Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 24. ACE inhibitors Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 25. ACE inhibitors Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 26. ACE inhibitors Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Angiotensin II receptor blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 28. Angiotensin II receptor blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Angiotensin II receptor blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Angiotensin II receptor blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Angiotensin II receptor blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Calcium channel blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Calcium channel blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Calcium channel blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Calcium channel blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Calcium channel blockers Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 38. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 43. Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Retail Pharmacy Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 48. Retail Pharmacy Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Retail Pharmacy Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Retail Pharmacy Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Retail Pharmacy Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Hospitals Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 53. Hospitals Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Hospitals Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Hospitals Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Hospitals Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table58. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Regional Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 63. Regional Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Regional Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Regional Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Regional Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 67. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 68. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 69. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 70. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 71. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 72. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 73. North America Antihypertensives Market Forecast End User 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 74. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 75. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table76. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 77. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 81. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 91. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 120. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 121. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 126. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Asia Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Asia Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Asia Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Asia Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Asia Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Asia Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. Asia Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Asia Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Asia Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Asia Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 137. Asia Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Asia Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Asia Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Asia Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Asia Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. RoAPAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. RoAPAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. RoAPAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. RoAPAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. RoAPAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165 Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167 Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168 Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170 Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179 Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182 Leading 10 Antihypertensives Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 183. Pfizer Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 184. Pfizer Inc. Antihypertensives Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 185. Pfizer Inc. Antihypertensives Product Offering (Segment, Product Offerings)
Table 186. Novartis AG Profile 2020 (CEO, HQ, Founded, Website)
Table 187. Novartis AG Antihypertensives Product Offering (Segment, Product Offerings)
Table 188. Merck & Co., Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 189. Merck & Co., Antihypertensives Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 190. Merck & Co., Antihypertensives Product Offering (Segment, Product Offerings)
Table 191. Boehringer Ingelheim GmbH Profile 2020 (CEO, HQ, Founded, Website)
Table 192. Boehringer Ingelheim GmbH Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 193. Boehringer Ingelheim GmbH Antihypertensives Product Offering (Segment, Product Offerings)
Table 194. Daiichi Sankyo Co. Ltd Profile 2020 (CEO, HQ, Founded, Website)
Table 195. Daiichi Sankyo Co. Ltd Antihypertensives Product Offering (Segment, Product Offerings)
Table 196. Johnson & Johnson Profile 2020 (CEO, HQ, Founded, Website)
Table 197. Johnson & Johnson Antihypertensives Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 198 Johnson & Johnson Antihypertensives Product Offering (Segment, Product Offerings)
Table 199. AstraZeneca PLC Profile 2020 (CEO, HQ, Founded, Website)
Table 200. AstraZeneca PLC Antihypertensives Product Offering (Segment, Product Offerings)
Table 201. AbbVie Profile 2020 (CEO, HQ, Founded, Website)
Table 202. AbbVie Antihypertensives Product Offering (Segment, Product Offerings)
Table 203. Cipla Limited Profile 2020 (CEO, HQ, Founded, Website)
Table 204. Cipla Limited Antihypertensives Product Offering (Segment, Product Offerings)
Table 205. Sun Pharmaceutical Industries Ltd Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 206. Sun Pharmaceutical Industries. Total Company Sales 2015-2020 (US$M, AGR %)
Table 207. Sun Pharmaceutical Industries. Product Offering (Segment, Product Offerings)
Table 208. Other Companies Involved in the Antihypertensives Market (Company, Location)
LIST OF FIGURES
Figure 1. Antihypertensives Market Type Overview
Figure 2. Antihypertensives Market By Type Overview
Figure 3. Antihypertensives Market By End User Overview
Figure 4 Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 5. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 6. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 7. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 8. Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 9. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 10. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 11. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 12. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 13. Antihypertensives Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 19. Antihypertensives Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 20. Antihypertensives Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 21. Antihypertensives Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 22. Antihypertensives Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 23. Antihypertensives Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 29. Regional Antihypertensives Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 30. Regional Antihypertensives Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 31. Regional Antihypertensives Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 32. Regional Antihypertensives Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 33. Regional Antihypertensives Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 34. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 35. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 36. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 37. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 38. North America Antihypertensives Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 39. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %)
Figure 40. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 41. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 42. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 43. North America Antihypertensives Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 44. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 45. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 46. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 47. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 48. North America Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 49. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 50. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 51. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 52. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 53. US Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 54. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 55. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 56. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 57. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 58. Canada Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 59. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M)
Figure 60. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 61. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 62. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 63. Europe Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 64. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M) (Before COVID)
Figure 65. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 66. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 67. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 68. Europe Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 69. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 70. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 71. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 72. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 73. Europe Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 74. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 75. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 76. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 77. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 78. UK Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 79. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 80. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 81. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 82. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 83. Germany Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 84. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 85. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 86. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 87. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 88. France Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 89. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 90. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 91. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 92. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 93. Rest of Europe Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 94 Asia-Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 95. Asia-Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 96. Asia-Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 97. Asia-Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 98. Asia-Pacific Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 99. Asia-Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 100. Asia-Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 101. Asia-Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 102. Asia-Pacific Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 103. Asia-Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 104. Asia-Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 105. Asia-Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 106. Asia-Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 107. Asia-Pacific Antihypertensives Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 108. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 109. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 110. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 111 China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 112. China Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 113. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 114. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 115. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 116. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 117. India Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 118. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 119. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 120. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 121. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 122. Japan Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 123. Rest of APAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 124. Rest of APAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 125 Rest of APAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 126. Rest of APAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 127. Rest of APAC Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 128. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M)
Figure 129. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 130. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 131. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 132. Middle East Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 133. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M)
Figure 134. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 135. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 136. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 137. Middle East Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 138. Rest of Middle East Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 139. Rest of Middle East Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 140. Rest of Middle East Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 141. Rest of Middle East Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 142. Rest of Middle East Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 143. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M)
Figure 144. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 145. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 146. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 147. Latin America Antihypertensives Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 148. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M)
Figure 149. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 150. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 151. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 152. Latin America Antihypertensives Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 153. Rest of Latin America Antihypertensives Market Forecast 2021-2031 (US$M, AGR %)
Figure 154. Rest of Latin America Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 155. Rest of Latin America Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 156. Rest of Latin America Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 157. Rest of Latin America Antihypertensives Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 158. Porter’s Five Force Analysis
Companies Mentioned
1. Pfizer Inc.
2. Novartis AG
3. Merck & Co., Inc
4. Boehringer Ingelheim GMBH
5. Daiichi Sankyo Co. Ltd
6. Johnson & Johnson
7. AstraZeneca plc
8. AbbVie
9. Cipla Limited
10. Sun Pharmaceutical Industries Ltd.
11. Sanofi
12. Mankind Pharma
13. Kenriz Care
14. Dr Reddy's Laboratories Ltd
15. Gilead Sciences, Inc.
16. Abbott Laboratories
17. Thermo Fisher Scientific
18. Takeda Pharmaceutical Company Ltd.
19. Astellas Pharma, Inc
20. Bayer HealthCare AG
Companies Profiled in the Report
1. Pfizer, Inc.
2. Novartis AG
3. Merck & Co., Inc
4. Boehringer Ingelheim GmbH
5. Daiichi Sankyo Co. Ltd
6. Johnson & Johnson
7. AstraZeneca PLC
8. AbbVie
9. Cipla Limited
10. Sun Pharmaceutical Industries Ltd.
11. Sanofi
12. Mankind Pharma
13. Kenriz Care
14. Dr Reddy's Laboratories Ltd
List of Companies Mentioned in the Report:
1. Pfizer Inc.
2. Novartis AG
3. Merck & Co., Inc
4. Boehringer Ingelheim GmbH
5. Daiichi Sankyo Co. Ltd
6. Johnson & Johnson
7. AstraZeneca PLC
8. AbbVie
9. Cipla Limited
10. Sun Pharmaceutical Industries Ltd.
11. Sanofi
12. Mankind Pharma
13. Kenriz Care
14. Dr Reddy's Laboratories Ltd
15. Gilead Sciences, Inc.
16. Abbott Laboratories
17. Thermo Fisher Scientific
18. Takeda Pharmaceutical Company Ltd.
19. Astellas Pharma, Inc
20. Bayer HealthCare AG
List of Organizations Mentioned in the Report
1. American College of Cardiology
2. American Heart Association
3. American Society of Nephrology
4. Center for Disease Control and Prevention CDC
5. Center for Diseases Dynamics, Economics & Policy (CDDEP)
6. Drug Office
7. Department of Health
8. Society of Cardiology Arterial Hypertension Department
9. European Society of Cardiology (ESC)
10. National Association for Biomedical Research
11. National Institutes of Health
12. Organic Process Research & Development
13. The European Medicines Agency (EMA)
14. The Global Health Security Agenda (GHSA)
15. U.S. Department of Health & Human Services
16. US Food & Drug Administration
17. US National Library of Medicine
18. World Hypertension League
19. World Health Organization
20. Heart Failure Society of America
1. Pfizer, Inc.
2. Novartis AG
3. Merck & Co., Inc
4. Boehringer Ingelheim GmbH
5. Daiichi Sankyo Co. Ltd
6. Johnson & Johnson
7. AstraZeneca PLC
8. AbbVie
9. Cipla Limited
10. Sun Pharmaceutical Industries Ltd.
11. Sanofi
12. Mankind Pharma
13. Kenriz Care
14. Dr Reddy's Laboratories Ltd
List of Companies Mentioned in the Report:
1. Pfizer Inc.
2. Novartis AG
3. Merck & Co., Inc
4. Boehringer Ingelheim GmbH
5. Daiichi Sankyo Co. Ltd
6. Johnson & Johnson
7. AstraZeneca PLC
8. AbbVie
9. Cipla Limited
10. Sun Pharmaceutical Industries Ltd.
11. Sanofi
12. Mankind Pharma
13. Kenriz Care
14. Dr Reddy's Laboratories Ltd
15. Gilead Sciences, Inc.
16. Abbott Laboratories
17. Thermo Fisher Scientific
18. Takeda Pharmaceutical Company Ltd.
19. Astellas Pharma, Inc
20. Bayer HealthCare AG
List of Organizations Mentioned in the Report
1. American College of Cardiology
2. American Heart Association
3. American Society of Nephrology
4. Center for Disease Control and Prevention CDC
5. Center for Diseases Dynamics, Economics & Policy (CDDEP)
6. Drug Office
7. Department of Health
8. Society of Cardiology Arterial Hypertension Department
9. European Society of Cardiology (ESC)
10. National Association for Biomedical Research
11. National Institutes of Health
12. Organic Process Research & Development
13. The European Medicines Agency (EMA)
14. The Global Health Security Agenda (GHSA)
15. U.S. Department of Health & Human Services
16. US Food & Drug Administration
17. US National Library of Medicine
18. World Hypertension League
19. World Health Organization
20. Heart Failure Society of America
Download sample pages
Complete the form below to download your free sample pages for Antihypertensives Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Antihypertensives Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
